---
title: "Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Limitations of current therapies"
description: "Formulary evidence on Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Limitations of current therapies. Topics: Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens; Summary: toxicity and administration of chemotherapy-containing regimens; Summary: outcomes in HPV-negative disease; Summary: options after progression and for locoregional recurrence; 14 further topics. 18 evidence topics quoted from 22 sources."
canonical: "https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T21:46:22-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Limitations of current therapies

<a id="heading-2.2.2.1.7"></a>

## 2.2.2.1.7 Limitations of Current Therapies

<a id="topic-2.2.2.1.7-1"></a>

### Summary: response, survival, and PD-L1 selection with first-line pembrolizumab regimens

Pembrolizumab monotherapy is approved for first-line recurrent or metastatic HNSCC with PD-L1 CPS ≥1, and pembrolizumab with platinum and fluorouracil for all first-line patients. ASCO states that “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”. At the KEYNOTE-048 4-year follow-up, the objective response rate with pembrolizumab alone was 19.1% versus 34.9% with cetuximab-chemotherapy in the CPS ≥1 population and 16.9% versus 36.0% in the total population; with pembrolizumab-chemotherapy it was 37.2% (CPS ≥1) and 36.3% (total). Neither pembrolizumab regimen improved progression-free survival at the second interim analysis, when median progression-free survival in the CPS ≥1 subgroup was 3.2 months with pembrolizumab versus 5.0 months with cetuximab-chemotherapy. At the 4-year follow-up, median overall survival was 12.3 months with pembrolizumab (CPS ≥1) and 13.0 months with pembrolizumab-chemotherapy (total population); 5-year overall survival in the total population was 14.4% and 16.0%, and the survival curve with pembrolizumab alone reached a plateau at approximately 20%. The median duration of pembrolizumab exposure was 3.5 months with monotherapy and 5.8 months in the combination arm. In exploratory analyses that were not prespecified, median overall survival with pembrolizumab alone versus cetuximab-chemotherapy was 10.8 versus 10.1 months in the CPS 1-19 subgroup (hazard ratio 0.86, 95% CI 0.66 to 1.12), and median overall survival was 7.9 versus 11.3 months in the CPS <1 subgroup (hazard ratio 1.51, 95% CI 0.96 to 2.37).

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328); [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/); [Burtness et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31679945/); [Tahara et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40262400/); [Burtness et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9287281/)

<a id="topic-2.2.2.1.7-2"></a>

### Summary: toxicity and administration of chemotherapy-containing regimens

At the KEYNOTE-048 4-year follow-up, grade ≥3 treatment-related adverse events occurred in 17.0% of participants receiving pembrolizumab alone, 71.7% receiving pembrolizumab-chemotherapy, and 69.3% receiving cetuximab-chemotherapy. Fluorouracil requires a “continuous 4-day infusion” and is associated with “cardiovascular and gastrointestinal toxicities”. In EXTREME, fatal cardiac disorders or sudden death occurred in 3% of 219 participants treated with cetuximab plus platinum and fluorouracil. With a taxane in place of fluorouracil alongside pembrolizumab and carboplatin, grade 3 to 5 treatment-related adverse events occurred in 76 of 101 treated participants (75%). NCI states that chemotherapy has been shown to induce responses with no demonstrated increase in survival; in randomized trials, cisplatin plus fluorouracil did not improve overall survival over methotrexate, and response rates were 32% with cisplatin plus fluorouracil and 10% with methotrexate in one trial, and 27% with cisplatin plus fluorouracil and 26% with cisplatin plus paclitaxel in another.

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/); [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/); [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf); [National Cancer Institute Lip and Oral Cavity Cancer Treatment PDQ (2025)](https://www.cancer.gov/types/head-and-neck/hp/adult/lip-mouth-treatment-pdq); [Forastiere et al. (1992)](https://pubmed.ncbi.nlm.nih.gov/1634913/); [Gibson et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15908667/)

<a id="topic-2.2.2.1.7-3"></a>

### Summary: outcomes in HPV-negative disease

Response and survival with current therapy are lower in HPV-negative than in HPV-positive disease. In Argiris et al. (2014), the objective response rate was 19% for HPV-negative versus 55% for HPV-positive tumors, and median survival was 6.7 versus 12.9 months. After progression of oropharyngeal cancer, 2-year overall survival was 27.6% for p16-negative versus 54.6% for p16-positive disease. With first-line pembrolizumab in U.S. practice, median real-world overall survival in HPV-negative versus HPV-positive disease was 9 versus 20 months on monotherapy and 7 versus 15 months with chemotherapy. ASCO states that current data “do not support changing recommendations” for anti-PD-1 therapy “with regard to the HPV status.”

Source: [Argiris et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4071756/); [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/); [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/); [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.7-4"></a>

### Summary: options after progression and for locoregional recurrence

The FDA states that approved therapies after platinum-based chemotherapy are associated with an overall response rate of around 20% or less. On November 5, 2026, amivantamab and hyaluronidase-lpuj received accelerated approval after progression on platinum-based chemotherapy and an anti-PD-(L)1 antibody, excluding HPV-associated oropharyngeal squamous cell carcinoma, based on an overall response rate of 42% in the 102-participant primary efficacy population of OrigAMI-4, a multicenter, open-label, multi-cohort trial. Conventional salvage regimens yield response rates of 21% to 69%, median progression-free survival of 2.9 to 5.5 months, and median overall survival of 6.3 to 13.3 months, and a review states that there is “no clear standard of care choice in second-line treatment”. For locoregional recurrence after prior radiation, reirradiation with intensity-modulated radiotherapy had pooled late grade ≥3 and grade 5 toxicity rates of 26% and 3.1%, and postoperative reirradiation with chemotherapy after salvage surgery improved disease-free survival without a significant effect on overall survival.

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma); [FDA (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-grants-accelerated-approval-amivantamab-and-hyaluronidase-lpuj-recurrent-or-metastatic-head-and); [Janssen RYBREVANT FASPRO prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761433s002lbl.pdf); [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/); [Lee et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32437021/); [Janot et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18936479/)

<a id="topic-2.2.2.1.7-5"></a>

### Response rates with pembrolizumab monotherapy

> “Response rates to single-agent pembrolizumab remain close to 20%, regardless of prior exposure to therapy or PD-L1 expression”

Source: [Yilmaz et al. (2023)](https://ascopubs.org/doi/10.1200/JCO.22.02328)

<a id="topic-2.2.2.1.7-6"></a>

### Objective response in KEYNOTE-048 at 4-year follow-up

> “Pembrolizumab alone did not improve ORR compared with cetuximab-chemotherapy in the PD-L1 CPS ≥ 20, CPS ≥ 1, or total populations”
> “The ORR was 23.3% (11 CR/20 PR) for pembrolizumab alone versus 36.1% (4 CR/40 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 19.1% (15 CR/34 PR) versus 34.9% (7 CR/82 PR) in the CPS ≥ 1 population, and 16.9% (15 CR/36 PR) versus 36.0% (8 CR/100 PR) in the total population”
> “The ORR was 43.7% (13 CR/42 PR) for pembrolizumab-chemotherapy versus 38.2% (4 CR/38 PR) for cetuximab-chemotherapy in the PD-L1 CPS ≥ 20 population, 37.2% (17 CR/73 PR) versus 35.7% (7 CR/77 PR) in the CPS ≥ 1 population, and 36.3% (18 CR/84 PR) versus 36.3% (8 CR/93 PR) in the total population”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-7"></a>

### Long-term survival plateau in KEYNOTE-048

> “A survival plateau at approximately 20% became apparent around the 4-year landmark for all patients receiving pembrolizumab alone. For patients receiving pembrolizumab-chemotherapy, a survival plateau at approximately 30% was observed for the PD-L1 CPS ≥ 20 population and at approximately 20% for the CPS ≥ 1 and total populations.”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-8"></a>

### Duration of pembrolizumab exposure in KEYNOTE-048

> “The median duration of exposure to KEYTRUDA was 3.5 months (range: 1 day to 24.2 months) in the KEYTRUDA single agent arm and was 5.8 months (range: 3 days to 24.2 months) in the combination arm.”

Source: [Merck KEYTRUDA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125514s191lblCorrected.pdf)

<a id="topic-2.2.2.1.7-9"></a>

### Treatment-related adverse events with pembrolizumab plus chemotherapy

> “Any-grade treatment-related AEs occurred in 58.3% (n = 175) of patients in the pembrolizumab-alone group, 95.7% (n = 264) in the pembrolizumab-chemotherapy group, and 96.9% (n = 278) in the cetuximab-chemotherapy group”
> “Grade ≥ 3 treatment-related AEs were reported in 17.0% (n = 51), 71.7% (n = 198), and 69.3% (n = 199) of patients, respectively”

Source: [Harrington et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9902012/)

<a id="topic-2.2.2.1.7-10"></a>

### Fluorouracil administration and toxicity

> “However, FU is associated with potential challenges (continuous 4-day infusion, high administration costs, and cardiovascular and gastrointestinal toxicities), creating a clinical need for alternative chemotherapy combinations.”

Source: [Dzienis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11361359/)

<a id="topic-2.2.2.1.7-11"></a>

### Cardiac deaths with cetuximab plus platinum and fluorouracil

> “In EXTREME, fatal cardiac disorders and/or sudden death occurred in 3% of 219 patients treated with a cetuximab product in combination with platinum-based therapy and fluorouracil.”

Source: [ImClone ERBITUX prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125084s279lbl.pdf)

<a id="topic-2.2.2.1.7-12"></a>

### HPV-negative disease: response and survival with first-line chemotherapy

> “The objective response rate was 55% for HPV-positive versus 19% for HPV-negative (P = 0.022), and 50% for p16-positive versus 19% for p16-negative (P = 0.057).”
> “The median survival was 12.9 versus 6.7 months for HPV-positive versus HPV-negative patients (P = 0.014), and 11.9 versus 6.7 months for p16-positive versus p16-negative patients (P = 0.027).”

Source: [Argiris et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4071756/)

<a id="topic-2.2.2.1.7-13"></a>

### HPV-negative disease: survival after progression of oropharyngeal cancer

> “patients with p16-positive OPC had significantly improved survival rates compared with p16-negative patients (2-year OS, 54.6% v 27.6%; median, 2.6 v 0.8 years; P < .001).”

Source: [Fakhry et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4195851/)

<a id="topic-2.2.2.1.7-14"></a>

### HPV-negative disease: real-world survival with first-line pembrolizumab

> “Among those receiving pembrolizumab monotherapy, the median rwOS was 20 months for those with HPV-positive tumors versus 9 months for those with HPV-negative tumors”
> “Among individuals receiving pembrolizumab plus chemotherapy, the median rwOS was 15 months for those with HPV-positive tumors versus 7 months for those with HPV-negative tumors”

Source: [Black et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10241070/)

<a id="topic-2.2.2.1.7-15"></a>

### Prognosis and later-line options before immunotherapy

> “The prognosis of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) remains poor, with a guarded median overall survival (OS) ranging from 10 months to 14 months”
> “Upon progression, the only treatment option was single-agent chemotherapy, with limited response rates and a median survival of 6 months”

Source: [Llop et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11625818/)

<a id="topic-2.2.2.1.7-16"></a>

### Few effective treatment options

> “There are few effective treatment options for patients with recurrent or metastatic head-and-neck squamous cell carcinoma.”

Source: [Cohen et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30509740/)

<a id="topic-2.2.2.1.7-17"></a>

### Unmet need stated by the FDA

> “HNSCC is an aggressive, life-threatening disease for which there is a high unmet need for effective therapies.”
> “a disease where treatment options have historically been limited and outcomes remain poor”

Source: [FDA press announcement (2026)](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-new-treatment-head-and-neck-squamous-cell-carcinoma)

<a id="topic-2.2.2.1.7-18"></a>

### Unmet need after immune checkpoint inhibitor failure

> “The challenge of R/M HNSCC after immune checkpoint inhibitor (ICI) failure represents one of the most pressing unmet needs in oncology.”
> “Between 60 and 80% of patients develop resistance, and historical salvage regimens like cytotoxic chemotherapy or chemotherapy plus cetuximab rarely extend median overall survival (mOS) beyond one year.”

Source: [Abraham et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12691436/)

## Related pages
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Terms and abbreviations](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/terms-and-abbreviations.md)
- [Ficerafusp alfa (BCA101): First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/executive-summary.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Product information and disease description](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/product-information-and-disease-description.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Clinical evidence](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/clinical-evidence.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: Economic information and modeling report](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/economics.md)
- [Ficerafusp alfa (BCA101) in First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab: References](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references) · [Markdown](https://www.evicenter.com/drugs/ficerafusp-alfa--first-line-recurrent-or-metastatic-hpv-negative-head-and-neck-squamous-cell-carcinoma-in-combination-with-pembrolizumab/references.md)
